132 related articles for article (PubMed ID: 23446068)
1. A 3-year, open-label, flexible-dosing study of milnacipran for the treatment of fibromyalgia.
Arnold LM; Palmer RH; Ma Y
Clin J Pain; 2013 Dec; 29(12):1021-8. PubMed ID: 23446068
[TBL] [Abstract][Full Text] [Related]
2. A pooled analysis of two randomized, double-blind, placebo-controlled trials of milnacipran monotherapy in the treatment of fibromyalgia.
Geisser ME; Palmer RH; Gendreau RM; Wang Y; Clauw DJ
Pain Pract; 2011; 11(2):120-31. PubMed ID: 20642487
[TBL] [Abstract][Full Text] [Related]
3. Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension study.
Goldenberg DL; Clauw DJ; Palmer RH; Mease P; Chen W; Gendreau RM
Pain Med; 2010 Feb; 11(2):180-94. PubMed ID: 20002596
[TBL] [Abstract][Full Text] [Related]
4. Short-term (2-week) effects of discontinuing milnacipran in patients with fibromyalgia.
Saxe PA; Arnold LM; Palmer RH; Gendreau RM; Chen W
Curr Med Res Opin; 2012 May; 28(5):815-21. PubMed ID: 22429066
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial.
Arnold LM; Gendreau RM; Palmer RH; Gendreau JF; Wang Y
Arthritis Rheum; 2010 Sep; 62(9):2745-56. PubMed ID: 20496365
[TBL] [Abstract][Full Text] [Related]
6. Preliminary experience using milnacipran in patients with juvenile fibromyalgia: lessons from a clinical trial program.
Arnold LM; Bateman L; Palmer RH; Lin Y
Pediatr Rheumatol Online J; 2015 Jun; 13():27. PubMed ID: 26112278
[TBL] [Abstract][Full Text] [Related]
7. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial.
Clauw DJ; Mease P; Palmer RH; Gendreau RM; Wang Y
Clin Ther; 2008 Nov; 30(11):1988-2004. PubMed ID: 19108787
[TBL] [Abstract][Full Text] [Related]
8. Relationships among pain, depressed mood, and global status in fibromyalgia patients: post hoc analyses of a randomized, placebo-controlled trial of milnacipran.
Arnold LM; Palmer RH; Gendreau RM; Chen W
Psychosomatics; 2012; 53(4):371-9. PubMed ID: 22677218
[TBL] [Abstract][Full Text] [Related]
9. A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia.
Branco JC; Zachrisson O; Perrot S; Mainguy Y;
J Rheumatol; 2010 Apr; 37(4):851-9. PubMed ID: 20156949
[TBL] [Abstract][Full Text] [Related]
10. Effects of milnacipran on the multidimensional aspects of fatigue and the relationship of fatigue to pain and function: pooled analysis of 3 fibromyalgia trials.
Mease PJ; Palmer RH; Wang Y
J Clin Rheumatol; 2014 Jun; 20(4):195-202. PubMed ID: 24847745
[TBL] [Abstract][Full Text] [Related]
11. Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial.
Clauw DJ; Mease PJ; Palmer RH; Trugman JM; Wang Y
Arthritis Res Ther; 2013 Aug; 15(4):R88. PubMed ID: 23953493
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial.
Mease PJ; Clauw DJ; Gendreau RM; Rao SG; Kranzler J; Chen W; Palmer RH
J Rheumatol; 2009 Feb; 36(2):398-409. PubMed ID: 19132781
[TBL] [Abstract][Full Text] [Related]
13. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
[TBL] [Abstract][Full Text] [Related]
14. Milnacipran: in fibromyalgia.
Chwieduk CM; McCormack PL
Drugs; 2010; 70(1):99-108. PubMed ID: 20030428
[TBL] [Abstract][Full Text] [Related]
15. Milnacipran effects on 24-hour ambulatory blood pressure and heart rate in fibromyalgia patients: a randomized, placebo-controlled, dose-escalation study.
Trugman JM; Palmer RH; Ma Y
Curr Med Res Opin; 2014 Apr; 30(4):589-97. PubMed ID: 24188161
[TBL] [Abstract][Full Text] [Related]
16. Longterm therapeutic response to milnacipran treatment for fibromyalgia. A European 1-year extension study following a 3-month study.
Branco JC; Cherin P; Montagne A; Bouroubi A;
J Rheumatol; 2011 Jul; 38(7):1403-12. PubMed ID: 21459941
[TBL] [Abstract][Full Text] [Related]
17. Safety profile and tolerability of up to 1 year of pregabalin treatment in 3 open-label extension studies in patients with fibromyalgia.
Arnold LM; Emir B; Murphy TK; Zeiher BG; Pauer L; Scott G; Petersel D
Clin Ther; 2012 May; 34(5):1092-102. PubMed ID: 22503162
[TBL] [Abstract][Full Text] [Related]
18. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia.
Vitton O; Gendreau M; Gendreau J; Kranzler J; Rao SG
Hum Psychopharmacol; 2004 Oct; 19 Suppl 1():S27-35. PubMed ID: 15378666
[TBL] [Abstract][Full Text] [Related]
19. Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial.
Matthey A; Cedraschi C; Piguet V; Besson M; Chabert J; Daali Y; Courvoisier D; Montagne A; Dayer P; Desmeules JA
Pain Physician; 2013; 16(5):E553-62. PubMed ID: 24077206
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of duloxetine 30 mg/d in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study.
Arnold LM; Zhang S; Pangallo BA
Clin J Pain; 2012; 28(9):775-81. PubMed ID: 22971669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
